NCT04739527CompletedPhase 1
An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Nov 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- First submitted
- 19 Aug 2024
- Start date
- 16 Sept 2024
- Lead sponsor
- Universitair Medisch Centrum Groningen
- Diseases
- Ovarian cancer
- NCT number
- NCT04739527
- EU CT number
- 2024-516781-10-00
- EudraCT number
- 2020-003600-13
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 17
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.